Summit Therapeutics SMMT Business Segments — Operating loss
Discontinued — last reported Q4 '24
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Summit Therapeutics’s 10-K, filed February 24, 2025, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's business segments — operating loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's business segments — operating loss?
- Summit Therapeutics (SMMT) reported business segments — operating loss of -$56.5M in Q4 2024.
- How has Summit Therapeutics's business segments — operating loss changed year-over-year?
- Summit Therapeutics's business segments — operating loss increased by 62.9% year-over-year, from -$152.41M to -$56.5M.
- What is the long-term trend for Summit Therapeutics's business segments — operating loss?
- Over 2 years (2022 to 2024), Summit Therapeutics's business segments — operating loss has grown at a 77.1% compound annual growth rate (CAGR), from -$72.09M to -$226M.
- What does business segments — operating loss mean?
- The financial loss incurred by the segment after accounting for all operating expenses related to its business activities.
- How do you interpret business segments — operating loss?
- A narrowing loss (moving toward zero) suggests improved cost management or potential revenue generation, while a widening loss indicates increased spending on R&D or operational scaling.
- How does business segments — operating loss compare across companies?
- Commonly reported as 'Segment Operating Profit/Loss' in industry peers, reflecting the stage of clinical development and the intensity of R&D spending relative to commercial progress.